Document Detail

Targeting the mineralocorticoid receptor in cardiovascular disease.
MedLine Citation:
PMID:  23324064     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Over the last two decades, the known functions of the mineralocorticoid receptor (MR) have expanded beyond regulation of sodium and potassium in epithelial cells to encompass physiological and pathophysiological effects in many tissues throughout the body. It is now well accepted that the MR plays a critical role in many aspects of cardiovascular disease.
AREAS COVERED: Recent studies employing tissue-selective MR null mice have added valuable insights into the cellular mechanisms that translate MR activation into cardiac remodeling and dysfunction. Together with earlier pharmacological studies using MR antagonists the apparent protective effects of tissue-selective MR deletion support the observed clinical benefits of MR antagonists in heart failure. Given the potential risk of side effects of current therapies, a key goal is the identification of tissue-selective MR antagonists that will provide cardiovascular protection, but spare renal function. As such, the specific cellular mechanisms regulated by MR located in the cardiovascular system may provide the basis for the development of targeted therapies.
EXPERT OPINION: This review will address the function of the MR, and its regulation of the cellular mechanisms that determine cell-specific MR signaling in cardiovascular disease and briefly discuss the potential for novel therapeutic targets that will allow for cardiac selective MR blockade.
Morag J Young
Related Documents :
11960054 - Comparison of sonohysterography and hysteroscopy: lessons learned and avoiding pitfalls.
11509394 - Pyelocalyceal diverticulum: the imaging spectrum with emphasis on the ultrasound features.
23514274 - A case of bilateral pleural effusion as the first sign of multiple myeloma.
23807514 - Three-dimensional mri-linac intra-fraction guidance using multiple orthogonal cine-mri ...
16355344 - Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 343...
11960054 - Comparison of sonohysterography and hysteroscopy: lessons learned and avoiding pitfalls.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2013-01-17
Journal Detail:
Title:  Expert opinion on therapeutic targets     Volume:  17     ISSN:  1744-7631     ISO Abbreviation:  Expert Opin. Ther. Targets     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-13     Completed Date:  2013-07-30     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101127833     Medline TA:  Expert Opin Ther Targets     Country:  England    
Other Details:
Languages:  eng     Pagination:  321-31     Citation Subset:  IM    
Monash University, Prince Henry's Institute of Medical Research, Cardiovascular Endocrinology Laboratory and Department of Physiology, Clayton, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiovascular Diseases / drug therapy,  metabolism*
Mineralocorticoid Receptor Antagonists / pharmacology,  therapeutic use
Receptors, Mineralocorticoid / metabolism*
Signal Transduction
Reg. No./Substance:
0/Mineralocorticoid Receptor Antagonists; 0/Receptors, Mineralocorticoid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The Trivalent Copper Complex of a Conjugated Bis-dithiocarbazate Schiff Base: Stabilization of Cu in...
Next Document:  Do 100- and 500-?T ELF magnetic fields alter beta-amyloid protein, protein carbonyl and malondialdeh...